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ABSTRACT: BACKGROUND. Recently, a new range of 
therapeutic options became available for men with advanced 
castration-resistant prostate cancer (CRPC), including antian-
drogens (abiraterone acetate, enzalutamide), taxanes (docetaxel, 
cabazitaxel) and a radionuclide (radium-223). The development 
of abiraterone and enzalutamide, as well as the advent of Ra-223, 
led to significant improvements in CRPC clinical outcomes. 
However, there are currently few data regarding the optimal 
sequence or concomitant use of Ra-223 with these most recently 
approved endocrine agents. OBJECTIVE. To systematically 
identify and analyse articles that brings information about the 
concomitant or sequential use of radium-223 (Ra-223) associated 
with antiandrogenic drugs (abiraterone or enzalutamide) in the 
therapy of CRPC. METHODS. PubMed (mesh and free terms), 
Scopus and Clinical Trials were searched to identify published 
articles about the sequential or association use of radium-223. 
RESULTS. A total of 484 references were identified by the 
literature search and after exclusion and inclusion criteria 36 
were screened. 4 publications that met the selection criteria were 
included in this review; of these 2 were cost-effectiveness studies 
and 2, case series. Overall, safety profiles in relation to therapy 
with Ra-223 were similar regardless of use or not of enzalutamide 
or abiraterone. Response were higher for the combinations of Ra-
223 with abiraterone while with enzalutamide no improvements 
were found. The drugs do not seem to have great differences in 
costs and there is still no consensus on the most cost-effective 
treatment in the short and long term. CONCLUSION. Further 
studies are necessary to evaluate the best treatment regimen 
(concurrent or sequential) of Ra-223 and new antiandrogens. 
By now, data show that the best association of use may be with 
abiraterone. There are ongoing clinical trials that aim to precisely 
study the use of these drugs together, therefore in the next few 
years this situation tends to change. 
Keywords: Radioisotopes; Prostatic neoplasms, castration-
resistant; Androgen  antagonists.
RESUMO: INTRODUÇÃO. Recentemente, uma nova gama 
de opções terapêuticas tornou-se disponível para homens com 
câncer de próstata resistente à castração (CPRC), incluindo 
anti-androgênios (acetato de abiraterona, enzalutamida), taxanos 
(docetaxel, cabazitaxel) e um radionuclídeo (rádio-223). O 
desenvolvimento de abiraterona e enzalutamida, bem como o 
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advento de Ra-223, levou a melhorias significativas nos resultados 
clínicos do CPRC. No entanto, existem atualmente poucos dados 
sobre a sequência ideal ou uso concomitante de Ra-223 com 
estes agentes endócrinos recentemente aprovados. OBJETIVO. 
Identificar e analisar sistematicamente os artigos que trazem 
informações sobre o uso concomitante ou sequencial de rádio-223 
(Ra-223) associado com drogas antiandrogênicas (abiraterona 
ou enzalutamida) na terapia de CPRC. MÉTODOS. PubMed 
(mesh e termos livres), Scopus e ensaios clínicos foram utilizados 
para identificar artigos publicados sobre o uso sequencial ou 
associação de rádio-223 com anti-androgênios(enzalutamida e 
abiraterona). RESULTADOS. Um total de 484 referências foram 
identificadas pela pesquisa bibliográfica e, após aplicar critérios de 
exclusão e inclusão, 36 foram selecionadas. Quatro publicações 
que atenderam aos critérios de seleção foram incluídas nesta 
revisão; destas, 2 são estudos de custo-eficácia e 2 são séries 
de casos. No geral, os perfis de segurança em relação à terapia 
com Ra-223 foram semelhantes independentemente do uso ou 
não de enzalutamida ou de abiraterona. As taxas de resposta 
ao tratamento  indicaram benefício na combinação de Ra-223 
com abiraterona, mas a combinação com enzalutamida não 
indicou evidências positivas. As drogas não parecem ter grandes 
diferenças em relação à despesa total e ainda não há um consenso 
sobre o tratamento mais viável economicamente no curto e longo 
prazo. CONCLUSÃO. Mais estudos são necessários para avaliar 
a melhor eficácia do tratamento concomitante ou sequencial de 
Ra-223 com os novos anti-androgênios. Até agora, os dados 
mostram que a melhor associação pode ser com abiraterona. Há 
ensaios clínicos em curso que visam estudar precisamente o uso 
desses medicamentos em conjunto, portanto, nos próximos anos, 
essa situação tende a mudar.
Descritores: Radioisótopos; Neoplasias de próstata resistentes 
à castração; Antagonistas de androgênios
INTRODUCTION
New therapies for advanced prostate cancer have been introduced in recent years, but it is not 
clear if the association or sequential use of different drugs 
may offer incremental response in this context. 
It is estimated that in the United States prostate 
cancer is responsible for 26% of new cancer cases in men 
and contributes with 9% of all cancer deaths. Furthermore, 
in Brazil this disease is responsible for 22% of new cancer 
cases1,2. Clinical presentation varies, ranging from early and 
localized disease to advanced, metastatic disease. Patients 
with metastatic prostate cancer are treated with classic 
anti-androgenic therapy aiming chemical castration in 
order to remove the most important stimulus for prostate 
cells proliferation. However, after 1 or 2 years of treatment 
it becomes ineffective, culminating in the clinical entity 
known as castration-resistant prostate cancer (CRPC)3. 
The first drug approved for the management 
of CRPC was mitoxantrone, based on studies that had 
shown palliative benefits, but not translated into improved 
survival4. Next, docetaxel demonstrated benefit in overall 
survival (average 2-3 months), and until 2010 no other 
substance had shown differences in this aspect5. However, 
most of the patients treated with docetaxel develop 
resistance to treatment and their disease progresses. 
Recently, a new range of therapeutic options as cabazitaxel, 
abiraterone acetate, enzalutamide, sipuleucel-T, and Ra-
223 became available, generating hope to change this 
paradigm6. 
With a better knowledge about the pathophysiology 
of CRPC, it was shown that the progression of the disease 
is still dependent on androgens, possibly due to structural 
and functional changes in the androgen receptor and its 
signaling pathway. It was concluded, therefore, that a more 
effective hormonal control to reduce plasma testosterone 
levels could be beneficial. The discovered evidence of the 
crucial role of androgen receptor led to the development of 
new anti-androgens such as enzalutamide and abiraterone 
acetate. The abiraterone acetate is a potent, irreversible 
inhibitor of cytochrome P450 17A1, which suppresses 
androgen synthesis and can act as an antagonist of 
the androgen receptor7. Similarly, enzalutamide is an 
antagonist of the androgen receptor that can block the 
binding of testosterone, preventing nuclear translocation 
of the androgen receptor, binding to DNA and recruiting 
coactivators8.
Along with the development of these drugs, new 
therapeutic agents that act on bone metastasis were also 
investigated. In advanced stages of this malignancy, 
bone metastasis are developed in 90% of patients with 
metastatic disease and have a significant impact on 
quality of life not only because of bone pain, but also 
due to the risks of bone events. A better understanding of 
the mechanisms associated with bone disease secondary 
to prostate cancer and the relation between tumor cells 
and the bone microenvironment were part of the basic 
knowledge that allowed the development of effective drugs 
for this situation, including the radium-223. Radium-223 
(Ra-223) is a calcium mimetic that preferentially binds to 
areas of newly formed bone in prostate bone metastases, 
being the first alpha radiation emitting radionuclide that 
has been developed for clinical use. The high energy 
transferred by the alpha particle causes irreversible 
double breaks in the DNA of tumor cells. The particles’ 
large size, when compared with other forms of radiation, 
results in a narrower range of action and highly localized 
tissue destruction, contributing, in theory, to mitigate bone 
marrow failure (BMF)9. 
The development of abiraterone and enzalutamide, 
as well as the advent of Ra-223, led to significant 
improvements in CRPC clinical outcomes. However, there 
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are currently few data regarding the optimal sequence or 
concomitant use of Ra-223 with the most recently approved 
endocrine agents.
OBJECTIVES
This systematic review aims to gather evidence 
about the concomitant use of Ra-223 associated with 
antiandrogenic drugs (abiraterone or enzalutamide) in the 
therapy of CRPC, focusing on the following endpoints: 
overall survival (OS), the occurrence of bone events 
(BE), survival free of skeletal related events (SRE), cost-
effectiveness (CE), pain reduction (PR), toxicity (T) and 
tolerance to treatment (TT).
METHODS
Evidence acquisition
For our research, the following databases were 
searched in April, 2016: MEDLINE (MeSH and free 
terms), Scopus and Clinical Trials. During the studies 
selection, the evaluation of titles and summaries (abstracts) 
identified in the initial search was conducted by two 
researchers independently, with any disagreements resolved 
by consensus. When the title and summary were not 
enlightening, the full article was analyzed.
The selected studies were categorized (clinical 
trials, case series, cost-effectiveness studies), and the 
information about the study design, study population, 
methodology, results and major conclusions recorded. The 
results were organized in tables and analyzed critically, 
seeking explanations for the different or conflicting results. 
Study selection
In MEDLINE, the following keywords and 
strategies were used: (“Prostatic Neoplasms, Castration-
Resistant” [mesh] OR “Prostatic Neoplasms” [mesh]) AND 
( “radium Ra 223 dichloride” [Supplementary Concept] OR 
“Radium / therapy use “[mesh] OR” Radium “[mesh]) AND 
(“ Androgen Antagonists “[mesh] OR” Androgen Receptor 
Antagonists “[mesh] OR” MDV 3100 “[Supplementary 
Concept] OR” abiraterone “[Supplementary Concept]). 
Another search was made for the free terms radium 223 
AND (prostatic neoplasms OR prostate cancer) AND 
(abiraterone OR enzalutamide OR MDV 3100 OR 
androgen antagonists OR androgen receptor antagonists), 
aiming to identify studies not yet indexed by descriptors.
In Scopus, the following keywords were used: 
alpharadin OR radium 223 OR xofigo AND prostate cancer 
AND abiraterone OR enzalutamide OR antiandrogens.
In the Clinical Trials platform there was made a 
survey of clinical trials records with Ra-223 that involved 
the sequential or combined use of enzalutamide or 
abiraterone.
Inclusion and exclusion criteria 
Articles identified by the initial search strategy 
were evaluated independently by two authors, according 
to the following inclusion criteria: (1) patients with CRPC; 
(2) use of Ra-223 associated or in sequential use with 
enzalutamide or abiraterone; (3) Description of clinical 
outcomes in terms of overall survival, pain reduction, cost-
effectiveness, skeletal event-free, survival or toxicity; (4) 
articles available for free or through subscriptions made by 
the University of São Paulo; (5) Article wrote in the period 
from 2013 to 2016. There were excluded from the analysis 
(1) review articles; (2) studies without clear description 
of the used medications and doses; (3) absence of clinical 
outcome description; (4) articles written in language other 
than English.
RESULTS
The search for mesh terms in MEDLINE resulted 
in 23 articles; review articles were excluded, remaining 5 
articles. In the analysis, none of them were selected due to 
the lack of information about the associated or sequential 
use of abiraterone or enzalutamide with Ra-223. 
The search for free terms in MEDLINE resulted 
in 115 articles, after excluding review articles and articles 
that were written out of the period from 2013 to 2016, 24 
articles were obtained and screened. From these, 8 were 
guidelines or recommendations of use and were therefore 
excluded, 12 were excluded due to the lack of information 
about the associated or sequential use of abiraterone or 
enzalutamide with Ra-223. 4 articles fitted in the criteria 
and were included (Table 1). 
In Scopus, the search resulted in 344 articles and 
after excluding review articles, articles written in language 
other than English and out of the period of selection, 65 
articles were obtained and screened. After excluding 
duplicates with MEDLINE and searching for association 
or sequential use, 3 congress posters were found but not 
included due to the lower reliability of the poster format 
(Figure 1).
In Clinical Trials platform, seven studies that fitted 
the criterias were found, but none with results currently 
available, so they were excluded from the analysis.
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Table 1. Summary of included articles
Authors Publication year
Research 
Design
Casuistry 
(n)
Comparison groups, 
intervention (treatment 
and doses)
Analyzed outcomes 
(toxicity, response or 
cost-effectiveness)
Major Results
Etchebehere 
EC, et al.10 2016 Case series 110
Before vs After use of 
radium-223 (50 kBq/kg, 1x 
for month, up to 6 cycles)
OS, PFD, BEFS, BMF, 
Hb, PSA, PA, ECOG, CT, 
EBRT, RaTot, AB, EZ
The associated use with 
abiraterone, but not 
enzalutamide seems to have 
a beneficial effect.
Dan TD,  
et al.13 2015 Case series 25
radium-223 (50kBq/kg, 1x 
month, for 6 cycles) alone 
vs radium-223 + EZ vs 
radium-223 + AB
Complete blood counts, 
Hb e PSA
Concomitant use of 
radium-223 with both 
anti-androgens have similar 
toxicity to its use alone.
Guirgis 
HM.11 2015
Cost-
effectiveness 
study
- radium-223 vs EZ vs AB
Cost for LYG,cost per 
likelihood of survival and 
relative values
AB, EZ, radium-223, were 
overpriced for their results
Bui CN,  
et al.12 2016
Cost-
effectiveness 
study
-
 EZ vs other drugs 
(including radium-223 and 
AB) in patients who have 
not received chemotherapy
IABI (PPPY, PPPM, 
PMPM)
Lower cost of 
administration, monitoring, 
and AE associated with the 
use of EZ compared with 
other treatment options.
Legend: overall survival (OS), progression free disease (PFD), bone events free survival (BEFS), bone marrow failure (BMF), hemoglobin (Hb), prostate 
specific antigen (PSA), alkaline phosphatase (AP), Eastern Cooperative Oncology Group (ECOG) status, chemotherapy (CT), external beam radiation 
therapy (EBRT), progression free survival (PFS), number of total Ra-223 cycles (RaTot), abiraterone (AB), enzalutamide (EZ), life year gained (LYG), 
incremental aggregate budget impact (IABI) per patient per year (PPPY), per patient per month (PPPM), and per member per month (PMPM). 
Figure 1. Summary of found and included articles
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Main results
In a retrospective review of 110 patients with 
metastatic CRPC treated with Ra-223, it was reported 
that 55 (50%) patients received anti-androgens prior to 
and 49 (45%) during or after Ra-223 therapy (Table 2)(10). 
Abiraterone was used in 69 patients and enzalutamide in 
30 cases. Interestingly, 36% of patients undergoing Ra-
223 therapy had visceral or lymph node metastases. Bone 
marrow failure was the major cause of death (88% of the 
cases), and had a significant correlation with the association 
of Ra-223 and external beam radiation, but not with the 
association of Ra-223 plus chemotherapy. In multivariate 
analysis total number of radium cycles (RaTot) and 
association of Ra-223 with abiraterone were the only ones 
who remained associated with overall survival (p < 0.001 
and p = 0.019, respectively), progression-free survival (p 
<0.001 and p = 0.041) and survival free of bony events 
(p <0.001 and p 0.019) (Table 3). Additionally, RaTot (p 
= 0.027) and EBRT (p = 0.013) remained significantly 
associated with BMF. There were clear benefit in OS (p 
≤ 0.008), bone events free survival (p < 0.020), and PFS 
(p < 0.003) with concomitant or after use of Ra-223 with 
abiraterone. In this population, patients receiving both 
drugs had a 77% reduction in the risk of death, 88% in the 
risk of bone related event and a 68% reduction in the risk 
of progression. Apparently, the study does not mention 
if the use of abiraterone before the Ra-223 is associated 
with a reduction in the evaluated parameters. The use of 
enzalutamide did not result in benefits in those patients in 
any of the endpoints evaluated10. 
Table 2. Results from study’ s variable analysis
Variables
OS PFS BMT BEFS
HR
p-value
HR
p-value
HR
p-value
HR
p-value
95% CI 95% CI 95% CI 95% CI
Univariate analysis
Abiraterone during/
after 0.23
0.002
0.32
<0.0001 N/E N/E
0.22
<0.001Ra-223 0.09 0.18 0.09 -
Yes vs No 0.58 0.55 0.51
Multivariate analysis
Abiraterone during/
after 0.32
0.035
0.53
0.044 N/E N/E
0.33
0.020Ra-223 0.11 0.28 0.31 -
Yes vs No 0.91 0.98 0.84
Table 3. Type and moment of treatment
Type of treatment prior, 
during and after
Before Ra-223 During/after 
Ra-223
Secundary hormonal therapy
Total, n (%) 55 (50) 49 (45
Abiraterone 38 31
Enzalutamide 16 14
In a cost-effectiveness study a model was applied 
to estimate the amount in United States dollars (US$) 
paid for life-year gain (LYG) and QALY in the treatment 
of pre-chemotherapy and chemo-treated patients with 
castrate-resistant metastatic prostate cancer (mCRPC)
(11). Information about the drugs were obtained from 
their respective phase III clinical trial: abiraterone COU-
AA-301 trial (1.000 mg oral during 1 year), enzalutamide 
AFFIRM (160mg oral during 1 year), Ra-223 ALSYMPCA 
(intravenous in 6 doses), including the gain in overall 
survival and the relative risk of death. The cost/LYG (life 
years gained) and cost/PoS (survival probability) were 
calculated both in US$ 230,000 for Ra-223, while the 
cost/LYG was 194,087 and 223,500 for abiraterone and 
enzalutamide, respectively.This costs were above the values 
proposed as a reference in the UK ($ 50,000/QALY (quality 
adjusted life-year) and in the United States ($50,000 for 
drugs that have a negative effect on patient’s quality of life 
(QoL) and $ 100,000 for drugs with improvement reported 
in terms of QoL). The work suggested that docetaxel, the 
only drug without patent, offered the best value for the 
money spent on the largest return value regardless of the 
relative risk or calculation used. All other drugs evaluated, 
including sipuleucel-T, abiraterone, enzalutamide, and 
Ra-223 were considered to have excessive costs for their 
returns11.
Other cost-effectiveness model was directed 
to evaluate the budget impact of enzalutamide for the 
treatment of metastatic CRPC in chemotherapy-naive 
patients, as compared to other drugs12. In their model, 
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adopting enzalutamide in the chemotherapy-naïve scenario 
had an annual incremental budget impact of $510,641, 
$4,426 per patient per year, $369 per patient per month, 
or $0.04 per member per month. Total treatment costs per 
patient in 12 months of enzalutamide was of U$102,204, 
of abiraterone was U$91.296 and of Ra-223 was U$81.780. 
Despite an increase in overall drug acquisition cost, the 
treatment of chemotherapy-naïve metastatic CRPC patients 
with enzalutamide was predicted to result in a savings of 
$4,186 in administration costs, $2,154 in monitoring costs, 
and $14,211 in adverse event costs over a 1-year time 
horizon compared to others options of therapy, including 
abiraterone and Ra-22312.
Finally, a retrospective study with 25 patients who 
received Ra-223 as part of standard care reported the blood 
counts and PSA variations after therapy13. Patients receiving 
Ra-223 alone and concurrently with next-generation 
antiandrogens were compared. Fourteen patients received 
concurrent therapy during monthly Ra-223 with either 
enzalutamide (n = 8) or abiraterone (n = 6). For patients 
receiving either Ra-223 alone and with concurrent next-
generation antiandrogen therapy, there did not appear to be 
any statistically significant differences between initial and 
nadir blood counts. Mean change from initial neutrophil 
count to nadir was 1.91/L in patients receiving Ra-223 
alone, versus 2.31/L in patients receiving concurrent 
therapy with antiandrogens (p = 0.77). Mean change from 
initial hemoglobin value to nadir was 1.5 g/L in patients 
receiving Ra-223 alone, versus 1.8 g/L in patients receiving 
concurrent therapy with antiandrogens (p = 0.31). Mean 
change from initial platelet count to nadir was 52.31 cells/L 
in patients receiving Ra-223 alone versus 70.61 cells/L in 
patients receiving concurrent therapy with antiandrogens 
(p = 0.39). PSA was stable or decreased in 22% of patients 
receiving Ra-223 alone versus 35% of patients receiving 
combination treatment with antiandrogens (P = 0.24)13.
DISCUSSION
Current overview of the treatment of mCRPC
Most prostate cancer patients treated with local or 
regional disease have positive outcomes, with a five-year 
survival rate near 100%. On the other hand, patients with 
metastatic prostate cancer at diagnosis have poor outcomes, 
with a median survival of approximately 3-4 years. The 
deprivation of androgens is the standard of care for the 
treatment of metastatic prostate cancer, since prostate 
cancer is the most sensitive of all cancers to endocrine 
therapy14,15.
The deprivation can be done by surgical or 
pharmacological castration and aims testosterone reduction 
below 50ng/dL. The luteinizing hormone releasing 
hormone (LHRH) agonists are equivalent to orchiectomy 
and/or estrogen in achieving the aimed level of testosterone 
reduction, have reversible effects, and are currently the 
preferred first-line treatment for patients with metastatic 
prostate cancer14. Medical alternatives to this monotherapy 
are less supported by clinical trial data, and include LHRH 
antagonists and combinations of an agonist or orchiectomy 
with an androgen receptor inhibitor16.
Evolution for castration-resistant prostate cancer 
affects nearly all patients with metastatic prostate cancer 
and is diagnosed by the following parameters: serum levels 
of testosterone lower than 50ng/dL, three consecutive 
increases in PSA levels, PSA progression despite intense 
hormonal manipulation, radiographic progression of 
bone lesions, or after at least 6 weeks of antiandrogens 
withdrawal17.
The treatment of CRPC has improved over the past 
decade when new treatments were shown to be effective 
when added to androgen deprivation therapy, although 
maintenance of androgen deprivation therapy remains 
many times a necessary component of the treatment even 
during second and third-line therapies of CRPC. At this 
moment, there is no consensus about the correct order to 
be followed to treat such patients but, in the current state 
of the art, it is suggested to initially assess the patient’s 
performance status and the spread of disease17.
For individuals tolerant to treatment and mildly 
symptomatic or asymptomatic a wide range of drugs such 
as docetaxel, abiraterone, sipuleucel-T, or enzalutamide 
might be used For patients who do not tolerate well the first-
line treatments and are asymptomatic, with no evidence 
of progression, it is suggested to offer regular monitoring 
and continued use of conventional anti-androgens (e.g., 
LHRH agonists). For men with symptomatic disease with 
or without visceral metastasis docetaxel may be indicated.
The use of Ra-223 is approved for patients with CRPC who 
have symptomatic bone metastases, yet no malignant lymph 
nodes larger than 3 cm or visceral metastases. It can be used 
both before and after use of docetaxel with equivalent gains 
in overall survival. It was also observed that patients who 
completed the treatment with the radiopharmaceutical had 
greater benefits than those who changed for chemotherapy 
without completing the 6 treatment cycles, thus, it might be 
important to note the functional status of the patient before 
starting Ra-223 therapy10. The second-line treatments 
will depend on the drugs used in the first-line and may 
be: cabazitaxel, Ra-223, docetaxel, enzalutamide and 
abiraterone17.
If there is evidence of advanced disease, it’s 
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recommended to start treating with docetaxel chemotherapy, 
and in the case of progression to indicate the use of 
abiraterone or enzalutamide as a second line treatment. 
If the disease is slowly progressive, poor symptomatic or 
without visceral metastases, abiraterone or enzalutamide 
can be recommended as first line treatment. However, 
with the benefits seen in the COU-AA-301 and AFFIRM 
trials and their better tolerability, it’s rational to consider 
abiraterone acetate or enzalutamide before chemotherapy 
in patients with contraindications to docetaxel or with poor 
general performance. Cross-resistance between abiraterone 
and enzalutamide, possibly related to the similarity in the 
mechanism of action, has been showed and there are also 
small, retrospective studies that, although with a potential 
bias due to the more advanced and aggressive disease, 
raise the possibility of decreased activity with docetaxel 
after either agent18,19.
After the second-line treatment other options 
are possible and depend on the functional status of the 
patient and the previous stages of treatment. In a third-line 
treatment setting docetaxel can be used again or another 
antiandrogen agent, Ra-223 or cabazitaxel17.
Ra-223 in combination with antiandrogens 
There are still very limited data regarding the 
association of Ra-223 with anti-androgens in CRPC. In 
the retrospective study of Etchebehere et al.10, it should 
be noticed that the number of patients taking abiraterone 
was more than twice that using enzalutamide. Such 
clinical preference may be based on the extrapolation of 
a possible synergistic interaction between abiraterone and 
radiotherapy, and the inference that the same may be true 
for the concomitant use of abiraterone and Ra-223, although 
other selection bias can not be ruled out13. Moreover, 
there is no information about whether the previous 
use of abiraterone with Ra-223 brought improvement 
in the evaluated parameters. Also, it is not possible to 
know whether the use of abiraterone was during or after 
treatment with Ra-223, which makes some other analysis 
of sequencing impossible.
Although there are no reports of increased incidence 
of bone marrow failure with the use of chemotherapy 
associated with Ra-223, the total number of cycles with Ra-
223 was associated with a higher incidence of BMF which 
diverges from previous clinical trials and other analysis of 
toxicity in our reach. The study population is recognized by 
the authors as very heterogeneous and differs from previous 
studies. Although patients achieved a survival time of 12 
months, shorter than the ALSYMPCA (median SG = 14 
months), the patient population was different from that 
study. In the initial diagnosis before the first cycle of Ra-
223, 82% of patients had skeletal tumor burden classified as 
high or intermediate, higher numbers than in ALSYMPCA 
study. Moreover, 12% had visceral metastases and 24% had 
lymph node metastasis and these patients were exclusion 
criteria of ALSYMPCA study. It arises, therefore, if in this 
population of patients with higher burden of disease or with 
visceral and lymph node metastases there are a higher risk 
of BMF in the treatment with Ra-223.
Besides the shown clear benefit of the associated use 
of Ra-223 with abiraterone, the reason why enzalutamide 
had not shown benefit in any of the parameters when 
associated with Ra-223 also deserves reflection and further 
analysis, maybe with more research. In the study the authors 
discuss that the comparative benefit of abiraterone against 
enzalutamide in this patient population could be due to a 
difference in patient selection, as in the case of patients 
who received abiraterone could have had a lower disease 
burden than those using enzalutamide. However, in that 
study, patients with metastatic CRPC initial ECOG status 
2 and 3 were more prevalent in the abiraterone group than 
enzalutamide group, 14% vs 7%, respectively. Similarly, 
there were more patients undergoing chemotherapy before 
Ra-223 in the abiraterone group than in enzalutamide group 
(51 vs 46% respectively). Therefore, patients using Ra-223 
and abiraterone had at least a similar load.
An ongoing study presented as a congress poster 
deserves mention, since it brings new data about this 
question19. The study is a phase IIIb trial, multicenter, 
prospective study that is checking the OS and the treatment 
safety of patients who have been treated with Ra-223. 
Among the 696 patients evaluated, 120 used abiraterone 
before treatment with Ra-223 and 25 used simultaneously, 
in addition, 59 patients used enzalutamide before therapy 
with Ra-223 and 15 concomitantly. The safety profiles in 
relation to therapy with Ra-223 were similar regardless 
of prior exposure or not to enzalutamide or abiraterone, 
similarly to the toxicity study included in this review19. 
Patients that had prior use of abiraterone or enzalutamide 
had also a higher rate of previous treatment with docetaxel 
and higher serum levels of alkaline phosphatase and 
PSA (theoretically they had a higher burden of disease 
and had been through more lines of treatment), but no 
significant variation in Ra-223 toxicity. Patients that used 
anti-androgens concomitant with Ra-223 were similar to 
those who did not use such drugs, except that PSA level 
and previous use of docetaxel were higher in the group 
with concomitant use of enzalutamide as compared to 
abiraterone or neither of the two drugs19,20. Contrarily to 
the study included in the review, in this prospective study 
patients that had used enzalutamide and Ra-223 were more 
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advanced in the disease and did not show improvement 
in overall survival10,19,20. Another fact to be noted is that 
among the patients who used abiraterone and Ra-223.32% 
had received prior enzalutamide. Among enzalutamide and 
Ra-223, 93% had received prior abiraterone, which may 
explain the lack of efficacy with enzalutamide due to cross-
resistance. Regarding the OS: OS of patients who received 
Ra-223 after treatment with abiraterone or enzalutamide 
appears to be similar to the rest of the population of 
the study and patients receiving therapy with Ra-223 
concurrently with enzalutamide or abiraterone (as first-
line therapies) a higher OS compared to the overall study 
population. It raises indications that prior therapy with 
antiandrogens does not alter the effectiveness of Ra-223.
The possibility of combination of Ra-223 with 
the new antiandrogens agents such as abiraterone and 
enzalutamide raises questions about their safety together. 
The literature indicates that the isolated treatment with 
each of these drugs has excellent tolerability profile. All 
included studies in this review and the mentioned poster, 
confirm that the Ra-223 combination with abiraterone and 
Ra-223 with enzalutamide has similar toxicity levels to 
those seen in patients who have exclusive use of therapy 
with Ra-22310,13,19,20. This seems to occur because the 
toxicity of antiandrogens does not overlap the toxicity of 
Ra-223 and allows a secure association and a new range 
of possibilities of treatment.
Regarding cost-effectiveness, the cost per LYG 
is high for all drugs previously mentioned11. This raises 
questions about the cost-effectiveness of these drugs in a 
public health system such as the Brazilian Unified Health 
System (SUS), although an adequate evaluation should 
be performed in this specific contexts. The other study 
assessing the budget impact of an imaginary population of 1 
million of habitants argued that the total spent on treatment 
with Ra-223 is significantly lesser than with abiraterone or 
enzalutamide, but enzalutamide compensated financially 
for generating further less side expenses12.
Another poster that was not included in this review 
deserves mention, this one assessing cost-effectiveness 
using the Markov’s model in patients previously treated 
with docetaxel, comparing Ra-223 with other drugs, 
including abiraterone and enzalutamide21. Effectiveness, 
symptomatic skeletal events (SSE’s), safety and QUALY’s 
were obtained from Phase III trials of such drugs through 
meta-analysis. SSE’s costs were taken from Dutch sources. 
The lifetime lower costs of Ra-223 in comparison with 
enzalutamide are driven by lower costs of drugs and, same 
as abiraterone, of SSE’s treatment costs21.
From all this information we might conclude that 
the cost of these drugs is significant in a scenario where 
the survival gains are modest due to the severity of the 
disease. The drugs do not seem to have great differences 
in relation to total spending and there is still no consensus 
on the most cost-effective treatment in the short and long 
term. Moreover, it is complex to transpose results from 
these studies in developed countries to Brazil, where the 
economic impact of these treatments on the health system 
may be greater. However, there is always a fair debate 
whether it is ethical to put a financial limit to effective 
treatments for serious illnesses like CRPC.
Considering the studies that directly evaluated the 
use of Ra-223 with abiraterone acetate or enzalutamide we 
must make some points. In one, 110 patients were evaluated 
while in the other only 2510,13. Furthermore, there was 
wide variation in the demographic spectrum of patients, 
the specters of disease and therapies previously and in 
current use. Moreover, both works consist of case series, 
with a low degree of evidence in the principles of evidence-
based medicine. Thus, for more detailed analysis and more 
accurate conclusions about the association and sequential 
use of Ra-223 with abiraterone acetate or enzalutamide, 
more robust studies in terms of sample size and degree of 
evidence are necessary22.
Future perspectives 
The main limitation of the present study was 
the scarcity of original articles about the association 
or concomitant use of Ra-223 with enzalutamide or 
abiraterone. This fact may be due to the actuality of 
the development and evaluation of these drugs (e.g. 
ALSYMPCA phase III trial were released in 2013), and to 
the delay in time from the entry of articles in the databases 
to complete indexation with medical subject heading 
(MeSH) terms. There are ongoing clinical trials that aim to 
precisely study the association or concomitant use of these 
drugs, therefore in the next few years this situation tends 
to change. We present below (Table 4) the current trials 
that englobe directly this topic or may provide new data 
to study the association or concomitant use of these drugs. 
CONCLUSION
Further studies are necessary to evaluate the best 
efficacy of concurrent or sequential treatment of Ra-223 
with the new antiandrogens, however, preliminary studies 
indicate that there may be a positive synergistic effect of 
abiraterone associated with Ra-223, a fact that, up to date, 
was not observed in Ra-223 association with enzalutamide. 
In addition, new evidence shows that concomitant or 
sequential treatment with these drugs does not impact on 
toxicity. The costs of these drugs are considerable and 
greater understanding of the effectiveness of the drugs and 
on the time of use or sequencing can lead to a more rational 
and cost-effective use10,13,19,20.
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Table 4. Current clinical trials
NCT02043678 NCT02034552 NCT02225704 NCT02729103 NCT02199197 NCT02097303 NCT02507570
Official Title 
A Phase III Randomized, 
Double-blind, Placebo-
controlled Trial 
of Radium-223 Dichloride 
in Combination With 
Abiraterone Acetate and 
Prednisone/Prednisolone 
in the Treatment of 
Asymptomatic or 
Mildly Symptomatic 
Chemotherapy-naïve 
Subjects With Bone 
Predominant Metastatic 
Castration-resistant 
Prostate Cancer (CRPC)
A Randomized Open-
label Phase IIa Study 
Evaluating Quantified 
Bone Scan Response 
Following Treatment 
With Radium-223 
Dichloride Alone or 
in Combination With 
Abiraterone Acetate 
or Enzalutamide 
in Subjects With 
Castration-resistant 
Prostate Cancer Who 
Have Bone Metastases
A Phase II Study 
of Radium-223 
in Combination 
With Enzalutamide 
in Progressive 
Metastatic Castrate-
Resistant Prostate 
Cancer
Treatment 
Patterns, Mortality, 
Healthcare Resource 
Utilization, and 
Costs in Patients 
With Prostate 
Cancer With 
Bone Metastases: 
A Retrospective 
Database Analysis
A Phase 2 
Randomized Study 
Comparing Radium Ra 
223 Dichloride Plus 
Enzalutamide With 
Enzalutamide Alone in 
Men With Metastatic 
Castration Refractory 
Prostate Cancer
Open Label Phase 
Two Trial of Radium 
Ra 223 Dichloride 
With Concurrent 
Administration of 
Abiraterone Acetate 
Plus Prednisone 
in Symptomatic 
Castration-Resistant 
(Hormone-
Refractory) Prostate 
Cancer Subjects With 
Bone Metastasis
Open Label Phase 
Two Study of 
Enzalutamide 
With Concurrent 
Administration 
of Radium Ra 
223 Dichloride in 
Castration-Resistant 
(Hormone-
Refractory) Prostate 
Cancer Subjects With 
Symptomatic Bone 
Metastasis
Estimated 
Completion 
Date
December 2020 June 2018 Not provided June 2016 June 2019 December 2015 Not provided
Estimated 
Primary 
Completion 
Date
December 2017 (final data 
collection date for primary 
outcome measure)
July 2016 (final data 
collection date for 
primary outcome 
measure)
December 2017 
(final data collection 
date for primary 
outcome measure)
June 2016 (final data 
collection date for 
primary outcome 
measure)
June 2019 (final data 
collection date for 
primary outcome 
measure)
December 2015   
(final data collection 
date for primary 
outcome measure)
February 2017 (final 
data collection date 
for primary outcome 
measure)
Recruitment 
Status Recruiting Active, not recruiting Recruiting Not yet recruiting Recruiting
Study completed 
(results not provided) Recruiting
Estimated 
Enrollment 800 62 44 1000 50 40 40
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